New antibodies to treat liver fibrosis
Therapeutic antibodies for treating liver fibrosis
This study is testing a new type of treatment using special antibodies to help people with liver fibrosis, a condition that can lead to serious liver problems, and aims to provide a safe option without the side effects of current treatments.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Abalone Bio, INC. NIH-funded |
| Lab location | 1 site (Emeryville, UNITED STATES) |
| Project ID | NIH-10666671 on NIH RePORTER |
What this research studies
This research focuses on developing therapeutic antibodies specifically designed to treat liver fibrosis, a condition that can lead to cirrhosis and is currently without approved drug treatments. The approach involves creating antibodies that selectively target the CB2 receptor, which plays a role in reducing liver fibrosis while avoiding the side effects associated with other treatments. By using a proprietary antibody discovery platform, the researchers aim to produce a long-lasting and safe treatment option that does not cross the blood-brain barrier, minimizing potential neurological side effects. Patients will be monitored for improvements in liver function and fibrosis progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with liver fibrosis or non-alcoholic steatohepatitis (NASH).
Not a fit: Patients with liver fibrosis caused by alcohol consumption or other non-targeted conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from liver fibrosis and related conditions.
How similar studies have performed: Previous research has shown promise in using cannabinoid receptor agonists for liver fibrosis, but this specific antibody approach is novel.
Where this research is happening
Emeryville, UNITED STATES
- Abalone Bio, INC. — Emeryville, United States (Active)
Researchers
- Principal investigator: Schwimmer, Lauren Jennifer — Abalone Bio, INC.
- Study coordinator: Schwimmer, Lauren Jennifer
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.